The TLR4/MyD88 axis in cancer: divergent and convergent roles of NF-κB and NLRP3 inflammasome activation and therapeutic opportunities.

Authors

Davood Zaeifi, Khadijeh Jamialahmadi, Gholamreza Karimi

Published in

Pharmacological research. Pages 109645. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

The TLR4/MyD88 signaling axis serves as a central hub linking microbial- and damage-associated molecular patterns to oncogenic inflammation. Upon ligand engagement, MyD88 orchestrates two major downstream branches, including the canonical NF-κB pathway, which drives transcriptional programs for cell survival, proliferation, angiogenesis, and metastasis, and the NLRP3 inflammasome, which amplifies IL-1β/IL-18 release and pyroptosis. While these branches have been extensively studied individually, their integrated roles and crosstalk remain underexplored in cancer. Recent advances show that NF-κB provides the essential signal 1 for NLRP3 priming, yet the two pathways exert cell-type- and tumor-stage-dependent, sometimes opposing effects on tumor progression, therapy resistance, and anti-tumor immunity. We highlight cancer-type and cell-type specificity, microbiome influences, and emerging therapeutic opportunities targeting TLR4, NF-κB, and NLRP3 individually or in combination. This unified framework positions the TLR4/MyD88 axis as a high-value target for precision oncology and underscores the need for pathway-selective inhibitors to harness its divergent outputs.

PMID:
42805516
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.